M42 expands Brazil footprint as Diaverum acquires four clinics
The clinics — CDTR and CDTR Prime in Sorocaba, INDI in Itapetininga, and Lund Nefrologia in Itu — bring Diaverum’s total to 18 clinics in Brazil, including three vascular access centres
24 April, 2026
TT
16
M42 said its renal care unit Diaverum has completed the acquisition of four clinics in Brazil’s São Paulo state from the Lund Group.
The clinics — CDTR and CDTR Prime in Sorocaba, INDI in Itapetininga, and Lund Nefrologia in Itu — bring Diaverum’s total to 18 clinics in Brazil, including three vascular access centres.
Chronic kidney disease is a major public health issue in Brazil, affecting more than 10 million people, many of whom are diagnosed at later stages, the company said. In São Paulo, the condition affects an estimated 6–9 per cent of the adult population, with around 2.3 per cent of those at stage 5 requiring dialysis.
Following the acquisition, Diaverum’s operations in Brazil are expected to deliver more than 220,000 treatments annually through a platform that includes owned clinics, public hospital partnerships and acute service agreements.
M42 said the deal supports its strategy to build globally connected care platforms from Abu Dhabi, in line with data sovereignty regulations, by integrating clinical expertise, digital infrastructure and chronic disease management.
“At M42, we are building a globally scaled health intelligence platform that tackles some of the world’s most pressing health challenges, including chronic kidney disease,” said Dimitris Moulavasilis, GCEO of M42. “Our expansion in Brazil is not just about growth; it grants more people in Brazil access to high-quality renal care that empowers patients with clinical insights, predictive analytics and digital tools to support earlier intervention and better long-term health outcomes.”
M42’s Diaverum recently bought SENERP
The acquisition builds on Diaverum’s recent purchase of Serviço de Nefrologia Ribeirão Preto (SENERP) and includes management contracts in two public hospitals and acute service agreements.
“Brazil is a strategic market for Diaverum, not only because of its scale and growth potential, but because of the opportunity to continue advancing the standard of care for patients who rely on dialysis every day,” said Rafael Romanini, Diaverum CEO and COO for Europe and Latin America. “With M42, we are building a connected care model that delivers consistent, high-quality, patient-centred treatment across markets.”
The clinics in Itu and Itapetininga are the only private dialysis providers in those cities, while facilities in Sorocaba serve as regional hubs, the company said.
M42 said insights from high-volume markets such as Brazil would support innovation and care delivery across its global operations, as it expands its presence in international healthcare markets.






















